In the setting of the patient already treated with TAVR, there are studies suggesting a benefit of renin–angiotensin system inhibition in these patients undergoing TAVR for aortic stenosis, or at least in a notable proportion of them (29, 30). This evidence concerns the gene REN and aortic stenosis.